Moleculin Biotech Inc
MBRX
Company Profile
Business description
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
Contact
5300 Memorial Drive
Suite 950
HoustonTX77007
USAT: +1 713 300-5160
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
17
Stocks News & Analysis
stocks
The strange effect of the 30% minimum capital gains tax
How the proposed CGT floor creates unexpected outcomes across different incomes.
stocks
Major ASX miner reduces aluminium exposure
The Alcoa transaction unlocks value and sharpens ASX miners focus on base metals.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,004.70 | 38.80 | -0.43% |
| CAC 40 | 8,497.34 | 17.47 | 0.21% |
| DAX 40 | 25,667.81 | 150.08 | -0.58% |
| Dow JONES (US) | 53,055.91 | 155.84 | 0.29% |
| FTSE 100 | 10,684.45 | 32.68 | 0.31% |
| HKSE | 23,496.89 | 119.43 | -0.51% |
| NASDAQ | 26,121.16 | 288.49 | 1.12% |
| Nikkei 225 | 68,256.96 | 1,480.73 | -2.12% |
| NZX 50 Index | 13,762.79 | 0.31 | -0.00% |
| S&P 500 | 7,537.43 | 54.19 | 0.72% |
| S&P/ASX 200 | 8,803.90 | 35.50 | -0.40% |
| SSE Composite Index | 3,990.24 | 51.00 | -1.26% |